Abstract
Background: Neurotransmitter signaling influences cancer initiation, progression, and therapy response. We systematically characterized the field’s intellectual structure, thematic evolution, and translational trajectory. Methods: We analyzed 2,823 Web of Science articles [2000–2025] with CiteSpace and Bibliometrix, and reviewed 76 interventional trials from ClinicalTrials.gov to assess translational activity, drug-class distribution, and trial design trends. Results: Annual output nearly tripled, with >50% of papers published after 2020. The US led productivity (26.2%) and impact; China showed rapid output growth (18.1%). Oncology trials with tumor efficacy endpoints were dominated by β-adrenergic antagonists (33%), histone deacetylase (HDAC) inhibitors (16%), selective serotonin reuptake inhibitors (SSRIs) (22%), and dopamine modulators (13%). Since 2018, immunotherapy combinations increased (8 trials). Trials were skewed toward early-phase, and trial design heterogeneity and limited biomarker integration were common. Translational linkage was limited: only 4.5% of publications connected to identifiable trials. The neurotransmitter-immune axis emerged as a central translational theme. Conclusions: Neurotransmitter-cancer research has expanded rapidly but shows substantial translational attrition. Findings support continued evaluation of β-blockers in late-phase trials, prioritized testing of SSRI-immunotherapy combinations, and exploration of underrepresented GABAergic and cholinergic pathways. We recommend harmonized preclinical-to-clinical pipelines and accelerated biomarker development to improve translation. This evidence-based map can guide targeted translational strategies in neurotransmitter-directed oncology and precision oncology.

This publication has 32 references indexed in Scilit: